Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201995887> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3201995887 endingPage "S451" @default.
- W3201995887 startingPage "S451" @default.
- W3201995887 abstract "Approximately a half of breast tumors traditionally classified as HER2-neg exhibit HER2-low expression (IHC 1+ or 2+ and ISH neg.). We recently described a high instability of HER2-low expression from primary breast cancer (BC) to relapse (Miglietta F et al., ESMO Breast Cancer 2021). Aim of this study is to track the evolution of HER2-low expression from primary BC to residual disease (RD) after neoadjuvant treatment. Patients undergoing neoadjuvant treatment with available baseline tumor tissue and matched samples of RD (in case of no pCR) were included. HER2 expression was evaluated according to ASCO/CAP recommendations in place at the time of diagnosis. Cases diagnosed between 2007 and 2013 were reviewed to comply with the 10% cutoff of IHC for HER2-positivity. HER2-neg cases were further classified as HER2-0 or HER2-low (IHC 1+ or 2+ and ISH neg.). 447 patients were included. Primary BC phenotype was: HR-pos/HER2-neg 23%, triple-negative (TN) 35%, HER2-pos 42%. HER2-low cases were 56% of the HER2-neg cohort and were significantly enriched in the HR-pos/HER2-neg vs TN subgroup (69% vs 47%, p=0.001). In patients failing to achieve pCR after neoadjuvant treatment (n=292), the overall rate of HER2 expression discordance was 27%, mostly driven by cases converting either from HER2-0 primary BC to HER2-low RD (9%) or from HER2-low primary BC to HER2-0 RD (15%; Table). Overall, 36% of non-pCR patients had a HER2-low expression on RD, including 12% of patients with TN and 24% of patients with HR-pos/HER2-neg disease. Among HR-pos/HER2-neg patients with HER2-low expression on RD, 23% had an estimated high risk of relapse according to the residual proliferative cancer burden (RPCB class 3).Table: 212PPrimary tumorResidual diseaseHER2-0HER2-lowHER2-posTotaln%n%n%n%HER2-05117269007726HER2-low431570241<111439HER2-pos0083933210135Total9432104369432292100 Open table in a new tab HER2-low expression showed high instability from primary BC to RD after neoadjuvant treatment. HER2-low expression on RD may guide personalized adjuvant treatment for high-risk patients in the context of clinical trials with novel anti-HER2 antibody-drug conjugates." @default.
- W3201995887 created "2021-10-11" @default.
- W3201995887 creator A5001331585 @default.
- W3201995887 creator A5013497028 @default.
- W3201995887 creator A5024264121 @default.
- W3201995887 creator A5034632931 @default.
- W3201995887 creator A5037416860 @default.
- W3201995887 creator A5046242778 @default.
- W3201995887 creator A5046301295 @default.
- W3201995887 creator A5055333835 @default.
- W3201995887 creator A5064741160 @default.
- W3201995887 creator A5068486162 @default.
- W3201995887 creator A5068906915 @default.
- W3201995887 creator A5074094118 @default.
- W3201995887 creator A5075407319 @default.
- W3201995887 creator A5085165482 @default.
- W3201995887 creator A5089001282 @default.
- W3201995887 date "2021-09-01" @default.
- W3201995887 modified "2023-10-16" @default.
- W3201995887 title "212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment" @default.
- W3201995887 doi "https://doi.org/10.1016/j.annonc.2021.08.494" @default.
- W3201995887 hasPublicationYear "2021" @default.
- W3201995887 type Work @default.
- W3201995887 sameAs 3201995887 @default.
- W3201995887 citedByCount "0" @default.
- W3201995887 crossrefType "journal-article" @default.
- W3201995887 hasAuthorship W3201995887A5001331585 @default.
- W3201995887 hasAuthorship W3201995887A5013497028 @default.
- W3201995887 hasAuthorship W3201995887A5024264121 @default.
- W3201995887 hasAuthorship W3201995887A5034632931 @default.
- W3201995887 hasAuthorship W3201995887A5037416860 @default.
- W3201995887 hasAuthorship W3201995887A5046242778 @default.
- W3201995887 hasAuthorship W3201995887A5046301295 @default.
- W3201995887 hasAuthorship W3201995887A5055333835 @default.
- W3201995887 hasAuthorship W3201995887A5064741160 @default.
- W3201995887 hasAuthorship W3201995887A5068486162 @default.
- W3201995887 hasAuthorship W3201995887A5068906915 @default.
- W3201995887 hasAuthorship W3201995887A5074094118 @default.
- W3201995887 hasAuthorship W3201995887A5075407319 @default.
- W3201995887 hasAuthorship W3201995887A5085165482 @default.
- W3201995887 hasAuthorship W3201995887A5089001282 @default.
- W3201995887 hasBestOaLocation W32019958871 @default.
- W3201995887 hasConcept C121608353 @default.
- W3201995887 hasConcept C126322002 @default.
- W3201995887 hasConcept C143998085 @default.
- W3201995887 hasConcept C204232928 @default.
- W3201995887 hasConcept C2778292576 @default.
- W3201995887 hasConcept C2779013556 @default.
- W3201995887 hasConcept C2779786085 @default.
- W3201995887 hasConcept C2780283643 @default.
- W3201995887 hasConcept C530470458 @default.
- W3201995887 hasConcept C71924100 @default.
- W3201995887 hasConceptScore W3201995887C121608353 @default.
- W3201995887 hasConceptScore W3201995887C126322002 @default.
- W3201995887 hasConceptScore W3201995887C143998085 @default.
- W3201995887 hasConceptScore W3201995887C204232928 @default.
- W3201995887 hasConceptScore W3201995887C2778292576 @default.
- W3201995887 hasConceptScore W3201995887C2779013556 @default.
- W3201995887 hasConceptScore W3201995887C2779786085 @default.
- W3201995887 hasConceptScore W3201995887C2780283643 @default.
- W3201995887 hasConceptScore W3201995887C530470458 @default.
- W3201995887 hasConceptScore W3201995887C71924100 @default.
- W3201995887 hasFunder F4320307105 @default.
- W3201995887 hasFunder F4320307765 @default.
- W3201995887 hasFunder F4320307778 @default.
- W3201995887 hasFunder F4320307779 @default.
- W3201995887 hasFunder F4320321781 @default.
- W3201995887 hasFunder F4320321966 @default.
- W3201995887 hasLocation W32019958871 @default.
- W3201995887 hasOpenAccess W3201995887 @default.
- W3201995887 hasPrimaryLocation W32019958871 @default.
- W3201995887 hasRelatedWork W1984009717 @default.
- W3201995887 hasRelatedWork W2003311516 @default.
- W3201995887 hasRelatedWork W2013223170 @default.
- W3201995887 hasRelatedWork W2066747782 @default.
- W3201995887 hasRelatedWork W2593886517 @default.
- W3201995887 hasRelatedWork W3092162558 @default.
- W3201995887 hasRelatedWork W4252376471 @default.
- W3201995887 hasRelatedWork W4322772378 @default.
- W3201995887 hasRelatedWork W812572266 @default.
- W3201995887 hasRelatedWork W2342209702 @default.
- W3201995887 hasVolume "32" @default.
- W3201995887 isParatext "false" @default.
- W3201995887 isRetracted "false" @default.
- W3201995887 magId "3201995887" @default.
- W3201995887 workType "article" @default.